CAR33VH

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug NameCAR33VH

Drug Alias Nameanti-CD33 CAR T-cell therapy (Lentigen Technology)CAR33VH

ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionMyeloid cell surface antigen CD33 modulators

TargetsMyeloid cell surface antigen CD33

Therapy Area/IndicationsLeukemia, Myeloid, Acute

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesLentigen Technology Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesLentigen Technology Inc

Active IndicationsN/A

Inactive IndicationsLeukemia, Myeloid, Acute

Other Information

ATC CodeN/A